Endometrium neoplasm

This early-phase trial is testing a personalized vaccine made from each patient's unique cancer mutations. The vaccine is designed to train the immune system to attack the cancer. Forty people with high-risk or recurrent endometrial cancer will receive the vaccine along with stan…

This study tests an experimental drug called AZD5305, a PARP inhibitor, either alone or combined with other cancer drugs in people with advanced solid tumors (like ovarian, breast, pancreatic, and lung cancers). The goal is to see if the treatment is safe and can shrink tumors. A…

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (with or without radiation) after surgery can help prevent high-risk endometrial cancer from coming back. About 990 participants who had surgery to remove their uterus and ovaries will r…

This study tests a new drug called SKB264 in people with advanced solid tumors that have not responded to standard therapies. The drug is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells. The trial includes over 1,400 participants with various …

This study tests a new drug called ARV-806 in adults with advanced solid tumors that have a specific KRAS G12D mutation. The drug aims to break down the mutated protein that helps tumors grow. The trial has two parts: first, finding a safe dose in small groups, then testing that …

This early-phase trial is testing an experimental drug called TTX-080, which blocks a protein (HLA-G) that tumors use to hide from the immune system. The study will give TTX-080 alone or combined with other cancer drugs (pembrolizumab, cetuximab, or FOLFIRI plus cetuximab) to abo…

This study tested a combination of two drugs, cabozantinib and nivolumab, in 82 people with advanced, recurrent, or metastatic endometrial cancer. The goal was to see if the combo could slow or stop cancer growth. Cabozantinib blocks enzymes that help tumors grow, while nivolumab…

This early-phase trial is testing a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (a drug that may block cancer cell repair)—in people with advanced solid tumors that have a HER2 mutation. The study has two parts: first, finding the sa…

This early-phase study tests the safety and best dose of a drug called veliparib when given with two chemotherapy drugs (carboplatin and paclitaxel) in people with advanced solid tumors that have spread or can't be removed. It includes patients who also have liver or kidney probl…

This pilot study tests whether hypofractionated radiation therapy, which gives higher doses over fewer sessions, is a practical option for people with non-metastatic cervical or endometrial cancer after hysterectomy. Researchers will measure bowel and urinary side effects using p…

This study tests a new drug, MK-2870, against standard chemotherapy in about 710 people with endometrial cancer that has worsened after platinum chemo and immunotherapy. The goal is to see if MK-2870 helps people live longer and delays cancer growth. Participants are randomly ass…

This study tests whether the drug selinexor can help keep advanced or recurrent endometrial cancer from growing back after initial chemotherapy. About 276 adults whose cancer has a normal p53 gene and who responded to platinum-based chemo will receive either selinexor or a placeb…

This early-stage trial tests a personalized cell therapy called ADP-A2M4CD8 in people with certain cancers that have a specific marker (MAGE-A4). The therapy uses a patient's own immune cells, modified to better attack tumors, and is given alone or with standard immunotherapy dru…

This study helps early-stage endometrial cancer survivors with obesity start a weight management program and possibly take weight loss medications. Researchers want to see if referring patients to a weight loss clinic helps them begin treatment. The goal is to improve long-term h…

This Phase 3 trial tests whether adding the immunotherapy drug durvalumab and the targeted therapy olaparib to standard chemotherapy can help women with newly diagnosed advanced or recurrent endometrial cancer live longer without their cancer growing. About 805 participants will …

This early-phase study tests a new oral drug, ATV-1601, in people with advanced solid tumors or certain breast cancers that have a specific AKT1 E17K mutation. The main goals are to check safety, find the right dose, and see how the drug moves through the body. About 134 adults w…

This phase 2 trial tests whether adding olaparib to selumetinib works better than selumetinib alone for women with recurrent or persistent ovarian or endometrial cancers that have a RAS pathway mutation. Selumetinib blocks enzymes that help cancer grow, while olaparib stops cance…

This phase III trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (paclitaxel and carboplatin) helps people with advanced (stage III or IV) or recurrent endometrial cancer. About 800 participants received either the combo or chemo alone. The …

This phase II trial is testing a combination of two drugs—atezolizumab (an immunotherapy) and bevacizumab (a drug that cuts off blood supply to tumors)—in 110 women with advanced, recurrent, or persistent endometrial cancer. The goal is to see how many patients experience tumor s…

This study tests a drug called sacituzumab govitecan against standard chemotherapy in 640 people with endometrial cancer that has come back after platinum-based chemo and immunotherapy. The goal is to see if the new drug can slow cancer growth and help people live longer. Partici…

This trial investigates whether the immunotherapy drug avelumab, given alone or combined with talazoparib or axitinib, can shrink tumors or slow disease progression in women with recurrent or persistent endometrial cancer. Participants have specific tumor types, including those w…

This phase 2 trial tests an experimental drug called disitamab vedotin in people with advanced head and neck, lung, endometrial, or ovarian cancers that have a protein called HER2. The drug is designed to stick to cancer cells and kill them. Researchers want to see if it shrinks …

This early-stage trial tests a specially modified virus (VSV-hIFNbeta-NIS) given through an IV to people with advanced or recurrent endometrial cancer. The virus is designed to attack cancer cells while leaving healthy cells alone, and it includes a tracer to see where it goes in…

This early-stage trial is testing a new oral drug called LY4066434, which blocks several types of KRAS proteins that drive cancer growth. The study includes up to 750 people with advanced pancreatic, lung, colorectal, or other solid tumors that have specific KRAS mutations. The d…

This study tests a combination of drugs (durvalumab, chemotherapy, and olaparib) as a first treatment for people with advanced or recurrent endometrial cancer that has a specific genetic marker (pMMR). The goal is to see how safe and tolerable the treatment is. About 85 people in…

This trial is for people with advanced cancers who have already responded well to 6 months of standard immunotherapy. It compares continuing the same drugs at the usual frequency versus giving them every 3 months. The goal is to see if the reduced schedule can prevent cancer prog…

This early-stage trial tests a new drug, ALTA2618, in about 110 adults whose advanced solid tumors (like breast or endometrial cancer) have a specific genetic change called AKT1 E17K. The main goals are to check the drug's safety and find the right dose. Participants must have tr…

This study tests a drug called TPST-1495 in people with endometrial or colorectal cancer who are scheduled for surgery. The drug aims to help the immune system fight cancer by blocking certain signals. Researchers will check blood and tumor samples before and after treatment to s…

This early-stage trial is testing a new drug called IDE161, alone or with the immunotherapy pembrolizumab, in adults with advanced solid tumors (like breast, ovarian, prostate, or lung cancer). The main goals are to check safety, find the right dose, and get a first look at wheth…

This study looks at whether a special program called Primary Care Connect (PC2) helps cancer survivors who also have conditions like high blood pressure, diabetes, or high cholesterol keep their heart risks under control during cancer treatment. About 266 adults with early-stage …

This early-stage trial tests a new drug called remzistotug, alone or with other cancer drugs, in 152 people with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose. It is not yet known if the drug will sh…

This phase 2 trial tests two drugs—niraparib and TSR-042 (dostarlimab)—in 51 women with recurrent endometrial cancer that has progressed after platinum chemotherapy. The goal is to see if these drugs can shrink or stabilize tumors. Niraparib blocks a protein that helps cancer cel…

This study tests an experimental drug, imlunestrant, in people with advanced or metastatic breast cancer that is estrogen-receptor positive (ER+), as well as certain other cancers like endometrial cancer. The drug is given alone or combined with other anticancer therapies. The ma…

This early-phase trial tests an experimental drug called IPH5301, which targets a protein called CD73 on cancer cells. The study involves 27 people with advanced solid tumors, including breast, lung, and pancreatic cancers. In the first part, IPH5301 is given alone to find a safe…

This early-stage trial tests a new treatment for people with advanced solid tumors that have a specific marker called CLDN6. The treatment uses specially engineered immune cells (CAR-T cells) that target CLDN6, sometimes combined with a genetic booster (RNA-LPX) to enhance their …

This early-phase study tests a new drug called BG-68501 in people with advanced solid tumors that have not responded to standard treatments. The drug targets a protein (CDK2) that helps cancer cells grow. The trial will check safety, find the right dose, and see if the drug shrin…

This study tests a drug called sacituzumab govitecan in 50 people with endometrial cancer that has returned or not responded to platinum chemotherapy. The drug works by delivering chemotherapy directly to cancer cells. The main goal is to see how many patients' tumors shrink or d…

This phase II trial tests whether adding pterostilbene, an antioxidant found in blueberries, to the hormone drug megestrol acetate can better slow endometrial cancer growth before hysterectomy. About 44 patients will receive either megestrol acetate alone or with pterostilbene fo…

This study is testing a new robotic system, the Medtronic Hugo™, for performing hysterectomies. It includes 70 patients with conditions like uterine fibroids, endometriosis, or certain cancers. The goal is to see if the robot is safe and can complete the surgery without switching…

This study tested a combination of two drugs—mirvetuximab soravtansine and pembrolizumab—in 18 people with a specific type of uterine cancer (endometrial cancer) that had returned or persisted and was microsatellite stable (MSS). The goal was to see if the combo could shrink tumo…

This study tests four different tools—coaching, education, text messages, and health coaching—to help cancer survivors improve their diet, physical activity, and weight. About 350 adults who have completed treatment for several cancer types will use these tools for up to 48 weeks…

This study tests an experimental drug called LY3537982 in people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to see if the drug is safe and shrinks tumors. About 540 participants with lung, colorectal, endometrial, ovarian, pancreatic, or bile …

This phase II trial tests whether adding ribociclib to a standard two-drug regimen (everolimus and letrozole) works better for people with advanced or recurrent endometrial cancer. About 90 participants will be randomly assigned to receive either the two-drug or three-drug combin…

This early-phase study tests whether combining two drugs, DKN-01 and pembrolizumab, can help control advanced or recurrent endometrial cancer that cannot be cured with surgery or radiation. Eight adult women with this type of cancer will receive the combination. The main goals ar…

This early-phase study tests a new drug called RMC-6291 in adults with advanced cancers (lung, colon, pancreatic) that have a specific KRAS G12C mutation. The goal is to find the safest dose and see how well the drug works. About 222 participants will receive the drug by mouth, a…

This early-phase trial tests the safety and best dose of two drugs, APG-1252 and cobimetinib, given together to people whose ovarian or endometrial cancer has come back. The drugs work by blocking proteins that help cancer cells survive and grow. The goal is to see if the combina…

This early-phase trial is testing whether adding the immunotherapy drug pembrolizumab to standard radiation and chemotherapy is safe and feasible for people with high-intermediate risk endometrial cancer. About 45 participants who have already had surgery to remove the uterus wil…

This Phase 3 trial compares the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy in 280 women with advanced or recurrent endometrial cancer that has a specific genetic feature (dMMR). The goal is to see if pembrolizumab can better delay cancer growth and impro…

This study tests whether giving the immunotherapy drug pembrolizumab before standard surgery can shrink tumors in people with a specific type of uterine cancer (MMRd). Twelve participants will receive 9 cycles of pembrolizumab before their hysterectomy. The goal is to see how man…

This phase II study tests whether the combination of letrozole (Femara) and everolimus (Afinitor) can help control advanced or recurrent endometrial cancer. The trial enrolled 42 participants whose cancer had progressed or returned. Researchers are measuring how many patients res…

This study was designed to test the safety and effectiveness of two drugs, bemarituzumab and bevacizumab, given together to people with advanced gynecologic cancers (endometrial, ovarian, or cervical) that have a specific protein called FGFR2b. The trial was withdrawn before enro…

This study tests a drug called ceralasertib, alone or with olaparib or durvalumab, in people with advanced solid tumors like kidney, bladder, pancreatic, and endometrial cancers. The goal is to see if these combinations can shrink tumors by blocking enzymes that help cancer grow.…

This study looks at whether giving chemotherapy after surgery can help people with early-stage (stage I-II) endometrial cancer who have a higher risk of the cancer coming back. About 244 patients will either receive six cycles of carboplatin and paclitaxel or simply be observed. …

This early-phase study tests two experimental immunotherapy drugs — botensilimab and balstilimab — alone and together in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and look for ea…

This study tests a new drug called E7386 combined with other cancer drugs in people with advanced solid tumors, including endometrial, liver, and colorectal cancers. The goal is to find the safest and most effective dose and to see if the combination can shrink tumors. About 300 …

This study tests a combination of two drugs, cadonilimab and lenvatinib, in 32 people with advanced endometrial cancer that has spread or come back and no longer responds to standard chemotherapy. The goal is to see if the combination shrinks tumors and how long it keeps the canc…

This study tests a combination of two drugs, abemaciclib and letrozole, in people with advanced or recurrent endometrioid endometrial cancer that cannot be cured by surgery or radiation. The main goal is to see how many participants have no cancer growth after 6 months of treatme…

This early-stage trial is testing a new drug called IMGN151 in 256 adults with recurrent gynaecological cancers, including ovarian, endometrial, and cervical cancers. The drug is an antibody-drug conjugate designed to deliver a cancer-killing agent directly to cells that have a s…

This phase 2 trial tests a new drug (ceralasertib) alone or combined with either olaparib or durvalumab in 174 people whose gynaecological cancer has returned. The study groups patients by their cancer type and whether they have a change in the ARID1A gene. The goal is to see if …

This study tests a new way for cancer doctors and primary care doctors to work together to help cancer survivors manage other health problems like high blood pressure, diabetes, and high cholesterol. About 800 adults with certain cancers and at least one of these conditions will …

This early-phase study tests a combination of two targeted drugs, palbociclib and gedatolisib, in people with advanced lung, pancreatic, head & neck, or other solid tumors that have stopped responding to standard treatments. The main goal is to find the safest dose and look for e…

This study tests a new combination of three FDA-approved drugs (lenvatinib, pembrolizumab, and paclitaxel) in women whose endometrial, ovarian, fallopian tube, or primary peritoneal cancer has returned after prior treatment. The goal is to see if the triple therapy shrinks tumors…

This early-phase study tests an experimental oral drug (GSK4418959) in adults with advanced solid tumors that have specific genetic changes (dMMR or MSI-H). The drug works by blocking a protein (WRN) that these tumors need to survive. The study aims to see if the drug, alone or w…

This study looks at whether adding metformin (a diabetes drug) to standard hormone therapy (megestrol acetate) works better to control uterine pre-cancer and stop it from turning into cancer. About 51 people with this pre-cancer condition will take one or both drugs before their …

This early-phase trial tests whether adding an immune-boosting drug (TSR-042) to standard radiation therapy is safe and effective for people with inoperable endometrial cancer. Ten participants with early-stage disease will receive both treatments. The goal is to see if the combi…

This phase 3 trial compares the immunotherapy drug dostarlimab with standard chemotherapy in 260 women with advanced or recurrent endometrial cancer that has a specific DNA repair defect (MMR deficient). The goal is to see if dostarlimab can better delay cancer progression and im…

This early-phase trial is testing a combination of two immunotherapy drugs, naptumomab estafenatox and durvalumab, in 120 people with advanced or metastatic solid tumors like pancreatic, ovarian, and lung cancer. The main goal is to find a safe dose and see how the body reacts. R…

This early-stage study tests a new drug called BL-M17D1 in 120 adults with advanced solid tumors that have HER2 protein or gene changes. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Participants must have tried at least one standard…

This phase 2 trial tests the immunotherapy drug pembrolizumab (Keytruda) in people with 15 types of advanced solid tumors that have worsened after standard treatments. About 1,600 participants receive the drug to see if their tumors shrink or stop growing. The study also looks fo…

This early-stage trial tests a radioactive imaging agent called RAD301 in 9 people: healthy volunteers and patients with pancreatic, lung, esophageal, cervical, endometrial, or ovarian cancer. The goal is to see how safe it is and how it travels through the body. If it works, it …

This study is testing whether a simple blood test can improve how doctors predict the risk of endometrial cancer returning after surgery. The test looks for tiny bits of tumor DNA and proteins in the blood before and after surgery. By combining this information with the current s…

This study tests whether injecting a radioactive sugar tracer (18F-FDG) into the cervix before a PET/CT scan can better show which pelvic lymph nodes contain cancer in women with early-stage cervical or high-grade endometrial cancer. The goal is to improve surgical planning by mo…

This study is testing whether a shorter course of pelvic radiation (called hypofractionation) is safe for women with endometrial cancer. The researchers will find the best dose and see if it reduces bowel and urinary side effects. About 100 women who have already had surgery will…

This study tests a newly designed vaginal speculum (the Bouquet Speculum) to see if it improves how doctors view the cervix, makes the biopsy procedure easier, and reduces patient discomfort. About 100 women aged 18-90 who have had a prior endometrial biopsy will take part. The g…

This study tests a newer type of radiation therapy called online adaptive radiotherapy (oART) for people who have had surgery for endometrial or cervical cancer. The goal is to see if using smaller treatment margins can reduce side effects while still effectively targeting any re…

This study tests whether group or one-on-one peer support helps Black patients with endometrial cancer complete their treatment and feel less isolated. About 252 participants will be randomly assigned to group support, one-on-one peer calls, or usual care. The main goal is to see…

This study is testing a program called Journey Ahead, designed to help women with gynecologic cancers improve their coping and communication skills. The researchers are enrolling 30 women who have been diagnosed with ovarian, endometrial, cervical, or uterine cancer. Participants…

This study looks at whether a 10-week exercise program done at home can improve physical fitness in women who have finished treatment for endometrial cancer. Ten participants will do exercises like chair stands and arm curls, guided by video coaching. The goal is to see if this a…

This study looks at whether a website and a genetic family navigator can help more relatives of people with hereditary cancer get genetic testing. About 205 participants will use the online hub and work with a navigator to learn about their cancer risk. The goal is to see if this…

This study follows women who have had pelvic exenteration—a surgery removing the lower colon, rectum, and bladder—for gynecologic cancers like cervical or endometrial cancer. Researchers want to see if factors like tumor size or surgery type affect complications, quality of life,…

This phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …

This study looks at how psychological distress and reproductive concerns affect young women's decisions about whether to keep their ovaries during surgery for early-stage endometrial cancer. Researchers will also examine whether women feel regret about their choice after the oper…

This study looks at risk factors for endometrial cancer in Black women, a group that may face different risks. Researchers will compare women recently diagnosed with the cancer to healthy volunteers, using questionnaires and interviews. The goal is to understand what factors matt…

This observational study looks at whether combining a blood test that detects tumor DNA (ctDNA) with a new genetic risk score can better predict if endometrial cancer will come back after surgery. Researchers will follow 52 women who had a hysterectomy for endometrial cancer, col…

This observational study collects extra tumor tissue from 416 people with various cancers (bladder, kidney, colorectal, head and neck, liver, lung, skin, endometrial) during routine biopsies. The goal is to develop and train a 'live tumor diagnostic platform' that can predict whe…

This long-running study follows nearly 100,000 French women, mostly teachers, since 1990 to understand what factors influence their risk of cancer, heart disease, diabetes, and other major illnesses. Participants fill out questionnaires every few years about their lifestyle, medi…

This study follows 21 patients who had a very extensive surgery called pelvic exenteration for recurrent gynecologic cancer. The goal is to understand how the surgery affects their quality of life and sexuality using standard questionnaires. The results will help doctors better p…

This study looks at pelvic floor problems and quality of life in people who survived uterine cancer. Researchers will use questionnaires to gather information from about 310 survivors treated with surgery at MD Anderson between 2006 and 2017. The goal is to better understand how …

This study follows 72 women with pelvic cancers (anal, cervical, endometrial, rectal, vaginal, or vulvar) who are receiving radiation therapy. Researchers will use pelvic exams and surveys to measure changes in vaginal health, sexual function, and quality of life over two years. …

This study looks back at 700 patients with endometrial cancer to compare two surgical approaches: minimally invasive surgery (laparoscopy) and open surgery (laparotomy). The goal is to see which method is safer and leads to better long-term outcomes, especially for patients at hi…

This study surveys women aged 18-45 diagnosed with gynecological or breast cancer to understand how they think about having children after treatment. Researchers aim to gather insights that could help future patients and survivors make informed choices about cancer treatment and …

This study is collecting blood and tumor samples from 300 people suspected of having ovarian, endometrial, or cervical cancer. Researchers will analyze the samples to find genetic changes that might predict how the cancer behaves. The goal is to better understand these cancers, n…

This study looks at how diet, lifestyle, and genetics influence the risk of endometrial cancer. Researchers will compare women who have or had the cancer with those who do not, using surveys and genetic analysis. The goal is to identify factors that may increase or decrease risk,…

This trial was designed to test whether an online mental health program could help women with advanced gynecologic or breast cancer manage their fear of the cancer returning or getting worse. The study planned to compare the online program to standard educational materials. Howev…

This study collects information from about 300 endometrial cancer patients across Asia to see how doctors use cancer cell features to choose treatments. The goal is to learn which patients need stronger therapy and which can avoid extra side effects. No new treatments are tested—…

This pilot study aimed to see if a mobile health app could help track symptoms and quality of life in people with recurrent head and neck or gynecologic cancers. Participants would have used the app to report their feelings, side effects, and barriers to care. However, the study …

This study follows 100 women with breast or gynecologic cancers to see if their diet before chemotherapy is linked to levels of a protein called hepcidin, and whether hepcidin levels affect how much chemo they can receive. The goal is to understand if eating certain foods might h…

This study looks at whether doctors can safely remove fewer lymph nodes during surgery for endometrial cancer by using a quick lab test during the operation. The goal is to reduce side effects like pain and swelling while still catching cancer that has spread. About 400 women wit…

This study looks at whether long-term inflammation raises the risk of endometrial cancer. Researchers are collecting blood and urine samples from 191 women having hysterectomy for either cancer or non-cancer reasons. They will compare markers of inflammation to better understand …

This study aimed to see if a type of PET/MRI scan could predict which women with early endometrial cancer or a precancerous condition would respond to hormone therapy. It planned to enroll 8 women and follow them for 6 months. However, the study was withdrawn before any participa…

The IMPACT Study is testing two online tools—GeneSHARE and LivingLabReport—to help people with inherited cancer gene variants share their results with family members and follow cancer screening guidelines. The study involves 720 adults who have a genetic variant linked to cancers…